Effects of ulipristal acetate in patients with symptomatic uterine fibroids.

Abstract

INTRODUCTION:

Uterine fibroids are frequently encountered in gynecology and are a therapeutic challenge. New therapies, such as ulipristal acetate, could help with symptomatic relief, improve quality of life, and decrease uterine fibroid size. Notwithstanding, there is controversy about adverse effects, especially for hepatotoxicity.

METHODS:

We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis, and generated a summary of findings table using the GRADE approach.

RESULTS AND CONCLUSIONS:

We identified nine systematic reviews and included ten studies overall, of which five were randomized trials. We conclude that ulipristal increases the likelihood of amenorrhea, improves the quality of life, and decreases menstrual bleeding. However, there is also a likely increase in the risk of adverse effects. Furthermore, ulipristal could decrease the size of fibroids.

• Authors: Natalia Navarro Plazaola, Marla Vega Chacana, Raimundo Avilés Dorlhiac
• Journal: Medwave (Medwave) Vol. 21 Issue 4 Pg. e8162 (May 07 2021) ISSN: 0717-6384 [Electronic] Chile
• Vernacular Title: Efectos del acetato de ulipristal en pacientes con miomas uterinos sintomáticos.
• PMID: 34086665 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Norpregnadienes
• ulipristal acetate

Topics

• Female
• Humans
• Leiomyoma (drug therapy)
• Norpregnadienes (therapeutic use)
• Quality of Life
• Systematic Reviews as Topic
• Treatment Outcome
• Uterine Neoplasms (drug therapy)